Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
2.455
-0.045 (-1.80%)
Oct 8, 2025, 1:58 PM EDT - Market open
Gossamer Bio Revenue
Gossamer Bio had revenue of $11.49M in the quarter ending June 30, 2025, a decrease of -88.01%. This brings the company's revenue in the last twelve months to $40.24M, down -58.02% year-over-year. In the year 2024, Gossamer Bio had annual revenue of $114.70M.
Revenue (ttm)
$40.24M
Revenue Growth
-58.02%
P/S Ratio
14.09
Revenue / Employee
$277,497
Employees
145
Market Cap
564.36M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 114.70M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GOSS News
- 13 days ago - Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital - PRNewsWire
- 13 days ago - Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension - Business Wire
- 16 days ago - Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Business Wire
- 27 days ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout - Seeking Alpha
- 5 weeks ago - Gossamer Bio to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 4 months ago - Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - Business Wire